Cowealth Medical China Co.Ltd. (603122) - Net Assets
Based on the latest financial reports, Cowealth Medical China Co.Ltd. (603122) has net assets worth CN¥1.05 Billion CNY (≈ $153.04 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.41 Billion ≈ $206.85 Million USD) and total liabilities (CN¥367.76 Million ≈ $53.81 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 603122 tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.05 Billion |
| % of Total Assets | 73.98% |
| Annual Growth Rate | 5.03% |
| 5-Year Change | 33.16% |
| 10-Year Change | N/A |
| Growth Volatility | 19.8 |
Cowealth Medical China Co.Ltd. - Net Assets Trend (2019–2025)
This chart illustrates how Cowealth Medical China Co.Ltd.'s net assets have evolved over time, based on quarterly financial data. See 603122 days of operational coverage to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Cowealth Medical China Co.Ltd. (2019–2025)
The table below shows the annual net assets of Cowealth Medical China Co.Ltd. from 2019 to 2025. For live valuation and market cap data, see Cowealth Medical China Co.Ltd. market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.06 Billion ≈ $155.06 Million |
-9.79% |
| 2024-12-31 | CN¥1.17 Billion ≈ $171.89 Million |
+0.49% |
| 2023-12-31 | CN¥1.17 Billion ≈ $171.05 Million |
-0.82% |
| 2022-12-31 | CN¥1.18 Billion ≈ $172.46 Million |
+48.11% |
| 2021-12-31 | CN¥795.77 Million ≈ $116.45 Million |
+10.98% |
| 2020-12-31 | CN¥717.02 Million ≈ $104.92 Million |
-9.17% |
| 2019-12-31 | CN¥789.41 Million ≈ $115.51 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Cowealth Medical China Co.Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 35.1% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥43.93 Million | 4.15% |
| Other Components | CN¥1.01 Billion | 95.85% |
| Total Equity | CN¥1.06 Billion | 100.00% |
Cowealth Medical China Co.Ltd. Competitors by Market Cap
The table below lists competitors of Cowealth Medical China Co.Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jiangsu Rainbow Heavy Industries Co Ltd
SHE:002483
|
$679.72 Million |
|
Shuifa Energas Gas Co Ltd
SHG:603318
|
$679.83 Million |
|
China National Complete Plant Import & Export Corp Ltd
SHE:000151
|
$679.86 Million |
|
Sichuan Dawn Precision Technology Co Ltd
SHE:300780
|
$679.93 Million |
|
Merida Industry Co Ltd
TW:9914
|
$679.16 Million |
|
Anhui Huilong Agricultural Means of Production Co Ltd
SHE:002556
|
$678.68 Million |
|
LiJiang YuLong Tourism Co Ltd
SHE:002033
|
$678.64 Million |
|
Maxic Technology Inc. A
SHG:688458
|
$678.64 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cowealth Medical China Co.Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,171,469,562 to 1,057,885,414, a change of -113,584,147 (-9.7%).
- Net loss of 33,642,991 reduced equity.
- Dividend payments of 52,659,834 reduced retained earnings.
- Other factors decreased equity by 27,281,322.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-33.64 Million | -3.18% |
| Dividends Paid | CN¥52.66 Million | -4.98% |
| Other Changes | CN¥-27.28 Million | -2.58% |
| Total Change | CN¥- | -9.70% |
Book Value vs Market Value Analysis
This analysis compares Cowealth Medical China Co.Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.39x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | CN¥2.64 | CN¥11.66 | x |
| 2020-12-31 | CN¥2.40 | CN¥11.66 | x |
| 2021-12-31 | CN¥2.67 | CN¥11.66 | x |
| 2022-12-31 | CN¥2.96 | CN¥11.66 | x |
| 2023-12-31 | CN¥2.93 | CN¥11.66 | x |
| 2024-12-31 | CN¥2.94 | CN¥11.66 | x |
| 2025-12-31 | CN¥2.66 | CN¥11.66 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cowealth Medical China Co.Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -3.18%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -4.96%
- • Asset Turnover: 0.47x
- • Equity Multiplier: 1.35x
- Recent ROE (-3.18%) is below the historical average (5.56%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 8.51% | 6.41% | 0.93x | 1.43x | CN¥-11.80 Million |
| 2020 | 10.12% | 6.66% | 0.98x | 1.55x | CN¥851.44K |
| 2021 | 10.08% | 6.74% | 1.06x | 1.41x | CN¥647.20K |
| 2022 | 7.02% | 6.46% | 0.82x | 1.32x | CN¥-35.05 Million |
| 2023 | 4.04% | 4.32% | 0.75x | 1.25x | CN¥-69.49 Million |
| 2024 | 2.35% | 2.94% | 0.63x | 1.28x | CN¥-89.58 Million |
| 2025 | -3.18% | -4.96% | 0.47x | 1.35x | CN¥-139.43 Million |
Industry Comparison
This section compares Cowealth Medical China Co.Ltd.'s net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $1,578,164,998
- Average return on equity (ROE) among peers: 23.23%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cowealth Medical China Co.Ltd. (603122) | CN¥1.05 Billion | 8.51% | 0.35x | $679.17 Million |
| Berry Genomics Co Ltd (000710) | $41.15 Million | 36.01% | 2.32x | $406.61 Million |
| Zhejiang DiAn Diagnostics Co (300244) | $110.32 Million | 15.56% | 0.62x | $1.67 Billion |
| Hangzhou Tigermed Consulting (300347) | $146.03 Million | 32.73% | 0.28x | $4.33 Billion |
| Beijing Strong Biotechnologies Inc (300406) | $385.67 Million | 35.53% | 0.12x | $972.92 Million |
| Ningbo MedicalSystem Biotechnology Co Ltd (300439) | $2.93 Billion | 8.79% | 0.26x | $470.71 Million |
| Maccura Biotechnology Co Ltd (300463) | $6.53 Billion | 10.85% | 0.25x | $742.36 Million |
| Guangdong Hybribio Biotech Co Ltd (300639) | $2.53 Billion | 14.31% | 0.13x | $505.18 Million |
| BGI Genomics Co Ltd (300676) | $150.37 Million | 54.36% | 5.67x | $2.17 Billion |
| Amoy Diagnostics Co Ltd (300685) | $1.70 Billion | 15.35% | 0.14x | $959.68 Million |
| Shanghai Labway Clinical Laboratory Co Ltd (301060) | $1.25 Billion | 8.85% | 0.18x | $507.55 Million |
About Cowealth Medical China Co.Ltd.
Cowealth Medical China Co.,Ltd. operates as a medical company in China. It offers centralized procurement services for in-vitro diagnostic reagents and consumables; platform for decision-making and analysis, commercialization of achievements in medical science and technology; a multi-channel coaxial time audio video imaging platform; and an AI-assisted system for clinical diagnosis. The company w… Read more